Literature DB >> 17297319

Ketamine attenuates early lipopolysaccharide-induced gastric dysfunction: role of stress-inducible phosphoproteins.

James W Suliburk1, David W Mercer.   

Abstract

BACKGROUND: Ketamine exerts anti-inflammatory actions and attenuates lipopolysaccharide (LPS)-induced gastric dysfunction by an unknown mechanism. Because stress-inducible phosphoproteins mediate many inflammatory responses, we hypothesized that ketamine would disrupt the early signaling events of LPS-induced inflammation by altering phosphorylation of stress-inducible phosphoproteins JNK, p38, and IkB.
METHODS: Adult rats received saline or ketamine (70 mg/kg, intraperitoneal) 1 hour before LPS (20 mg/kg, intraperitoneal) or saline. Animals were killed at 15, 30, 45, and 60 minutes after LPS, gastric mucosa was harvested, and gastric volume and pH were recorded. Gastric mucosal phosphorylation of JNK, p38, and IkB-alpha were analyzed with a multiplexed suspension immunoassay.
RESULTS: Ketamine-attenuated LPS induced increases in gastric luminal fluid and pH. Control animals receiving saline or ketamine and no LPS had gastric volumes of 0.1 mL and luminal pH of 2 at all time points. LPS upregulated phosphorylation of JNK, p38, and IkB-alpha as early as 15 minutes after LPS. Ketamine did not effect the early phosphorylation of these proteins.
CONCLUSION: Endotoxin causes gastric dysfunction and upregulates stress-inducible phosphoproteins within minutes after LPS. Although ketamine attenuates gastric dysfunction, its salutary effects do not seem to be related to alterations in phosphorylation of JNK, p38, or IkB-alpha.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17297319     DOI: 10.1097/01.ta.0000221755.84832.55

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  1 in total

1.  Ketamine promotes breast tumor growth in a mouse breast tumor model involving with high expression of miR-27b-3p and EGFR.

Authors:  Li-Kuei Chen; Chien-Hung Shih; Shiou-Sheng Chen; Zi-Xuan Huang; Yu-Jung Chang; Linyi Chen; Tsung-Hsien Chuang; Kuen-Bao Chen
Journal:  Invest New Drugs       Date:  2022-08-09       Impact factor: 3.651

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.